Research ExplorerPublicationsDynamics of CXCR4 positive circulating tumor cells in prosta...

Dynamics of CXCR4 positive circulating tumor cells in prostate cancer patients during radiotherapy

Standard

Dynamics of CXCR4 positive circulating tumor cells in prostate cancer patients during radiotherapy. / Klusa, Daria; Lohaus, Fabian; Franken, Andre; Baumbach, Marian; Cojoc, Monica; Dowling, Paul; Linge, Annett; Offermann, Anne; Löck, Steffen; Hušman, Dejan; Rivandi, Mahdi; Polzer, Bernhard; Freytag, Vera; Lange, Tobias; Neubauer, Hans; Kücken, Michael; Perner, Sven; Hölscher, Tobias; Dubrovska, Anna; Krause, Mechthild; Kurth, Ina; Baumann, Michael; Peitzsch, Claudia.

In: INT J CANCER, Vol. 152, No. 12, 15.06.2023, p. 2639-2654.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Klusa, D, Lohaus, F, Franken, A, Baumbach, M, Cojoc, M, Dowling, P, Linge, A, Offermann, A, Löck, S, Hušman, D, Rivandi, M, Polzer, B, Freytag, V, Lange, T, Neubauer, H, Kücken, M, Perner, S, Hölscher, T, Dubrovska, A, Krause, M, Kurth, I, Baumann, M & Peitzsch, C 2023, 'Dynamics of CXCR4 positive circulating tumor cells in prostate cancer patients during radiotherapy', INT J CANCER, vol. 152, no. 12, pp. 2639-2654. https://doi.org/10.1002/ijc.34457

APA

Klusa, D., Lohaus, F., Franken, A., Baumbach, M., Cojoc, M., Dowling, P., Linge, A., Offermann, A., Löck, S., Hušman, D., Rivandi, M., Polzer, B., Freytag, V., Lange, T., Neubauer, H., Kücken, M., Perner, S., Hölscher, T., Dubrovska, A., ... Peitzsch, C. (2023). Dynamics of CXCR4 positive circulating tumor cells in prostate cancer patients during radiotherapy. INT J CANCER, 152(12), 2639-2654. https://doi.org/10.1002/ijc.34457

Vancouver

Klusa D, Lohaus F, Franken A, Baumbach M, Cojoc M, Dowling P et al. Dynamics of CXCR4 positive circulating tumor cells in prostate cancer patients during radiotherapy. INT J CANCER. 2023 Jun 15;152(12):2639-2654. https://doi.org/10.1002/ijc.34457

Bibtex

@article{c6639ebe710c4629a031c7f01efbfaeb,
title = "Dynamics of CXCR4 positive circulating tumor cells in prostate cancer patients during radiotherapy",
abstract = "Ablative radiotherapy is a highly efficient treatment modality for patients with metastatic prostate cancer (PCa). However, a subset of patients does not respond. Currently, this subgroup with bad prognosis cannot be identified before disease progression. We hypothesize that markers indicative of radioresistance, stemness and/or bone tropism may have a prognostic potential to identify patients profiting from metastases-directed radiotherapy. Therefore, circulating tumor cells (CTCs) were analyzed in patients with metastatic PCa (n = 24) during radiotherapy with CellSearch, multicolor flow cytometry and imaging cytometry. Analysis of copy-number alteration indicates a polyclonal CTC population that changes after radiotherapy. CTCs were found in 8 out of 24 patients (33.3%) and were associated with a shorter time to biochemical progression after radiotherapy. Whereas the total CTC count dropped after radiotherapy, a chemokine receptor CXCR4-expressing subpopulation representing 28.6% of the total CTC population remained stable up to 3 months. At once, we observed higher chemokine CCL2 plasma concentrations and proinflammatory monocytes. Additional functional analyses demonstrated key roles of CXCR4 and CCL2 for cellular radiosensitivity, tumorigenicity and stem-like potential in vitro and in vivo. Moreover, a high CXCR4 and CCL2 expression was found in bone metastasis biopsies of PCa patients. In summary, panCK+ CXCR4+ CTCs may have a prognostic potential in patients with metastatic PCa treated with metastasis-directed radiotherapy.",
author = "Daria Klusa and Fabian Lohaus and Andre Franken and Marian Baumbach and Monica Cojoc and Paul Dowling and Annett Linge and Anne Offermann and Steffen L{\"o}ck and Dejan Hu{\v s}man and Mahdi Rivandi and Bernhard Polzer and Vera Freytag and Tobias Lange and Hans Neubauer and Michael K{\"u}cken and Sven Perner and Tobias H{\"o}lscher and Anna Dubrovska and Mechthild Krause and Ina Kurth and Michael Baumann and Claudia Peitzsch",
note = "This article is protected by copyright. All rights reserved.",
year = "2023",
month = jun,
day = "15",
doi = "10.1002/ijc.34457",
language = "English",
volume = "152",
pages = "2639--2654",
journal = "INT J CANCER",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "12",

}

RIS

TY - JOUR

T1 - Dynamics of CXCR4 positive circulating tumor cells in prostate cancer patients during radiotherapy

AU - Klusa, Daria

AU - Lohaus, Fabian

AU - Franken, Andre

AU - Baumbach, Marian

AU - Cojoc, Monica

AU - Dowling, Paul

AU - Linge, Annett

AU - Offermann, Anne

AU - Löck, Steffen

AU - Hušman, Dejan

AU - Rivandi, Mahdi

AU - Polzer, Bernhard

AU - Freytag, Vera

AU - Lange, Tobias

AU - Neubauer, Hans

AU - Kücken, Michael

AU - Perner, Sven

AU - Hölscher, Tobias

AU - Dubrovska, Anna

AU - Krause, Mechthild

AU - Kurth, Ina

AU - Baumann, Michael

AU - Peitzsch, Claudia

N1 - This article is protected by copyright. All rights reserved.

PY - 2023/6/15

Y1 - 2023/6/15

N2 - Ablative radiotherapy is a highly efficient treatment modality for patients with metastatic prostate cancer (PCa). However, a subset of patients does not respond. Currently, this subgroup with bad prognosis cannot be identified before disease progression. We hypothesize that markers indicative of radioresistance, stemness and/or bone tropism may have a prognostic potential to identify patients profiting from metastases-directed radiotherapy. Therefore, circulating tumor cells (CTCs) were analyzed in patients with metastatic PCa (n = 24) during radiotherapy with CellSearch, multicolor flow cytometry and imaging cytometry. Analysis of copy-number alteration indicates a polyclonal CTC population that changes after radiotherapy. CTCs were found in 8 out of 24 patients (33.3%) and were associated with a shorter time to biochemical progression after radiotherapy. Whereas the total CTC count dropped after radiotherapy, a chemokine receptor CXCR4-expressing subpopulation representing 28.6% of the total CTC population remained stable up to 3 months. At once, we observed higher chemokine CCL2 plasma concentrations and proinflammatory monocytes. Additional functional analyses demonstrated key roles of CXCR4 and CCL2 for cellular radiosensitivity, tumorigenicity and stem-like potential in vitro and in vivo. Moreover, a high CXCR4 and CCL2 expression was found in bone metastasis biopsies of PCa patients. In summary, panCK+ CXCR4+ CTCs may have a prognostic potential in patients with metastatic PCa treated with metastasis-directed radiotherapy.

AB - Ablative radiotherapy is a highly efficient treatment modality for patients with metastatic prostate cancer (PCa). However, a subset of patients does not respond. Currently, this subgroup with bad prognosis cannot be identified before disease progression. We hypothesize that markers indicative of radioresistance, stemness and/or bone tropism may have a prognostic potential to identify patients profiting from metastases-directed radiotherapy. Therefore, circulating tumor cells (CTCs) were analyzed in patients with metastatic PCa (n = 24) during radiotherapy with CellSearch, multicolor flow cytometry and imaging cytometry. Analysis of copy-number alteration indicates a polyclonal CTC population that changes after radiotherapy. CTCs were found in 8 out of 24 patients (33.3%) and were associated with a shorter time to biochemical progression after radiotherapy. Whereas the total CTC count dropped after radiotherapy, a chemokine receptor CXCR4-expressing subpopulation representing 28.6% of the total CTC population remained stable up to 3 months. At once, we observed higher chemokine CCL2 plasma concentrations and proinflammatory monocytes. Additional functional analyses demonstrated key roles of CXCR4 and CCL2 for cellular radiosensitivity, tumorigenicity and stem-like potential in vitro and in vivo. Moreover, a high CXCR4 and CCL2 expression was found in bone metastasis biopsies of PCa patients. In summary, panCK+ CXCR4+ CTCs may have a prognostic potential in patients with metastatic PCa treated with metastasis-directed radiotherapy.

U2 - 10.1002/ijc.34457

DO - 10.1002/ijc.34457

M3 - SCORING: Journal article

C2 - 36733230

VL - 152

SP - 2639

EP - 2654

JO - INT J CANCER

JF - INT J CANCER

SN - 0020-7136

IS - 12

ER -